Intech Biopharm Corporation (TPEX:6461)
Taiwan · Delayed Price · Currency is TWD 16.10
-0.35 (-2.13%)
Jul 9, 2026, 2:31 PM CST
Intech Biopharm Company Description
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally.
The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules.
Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.
Intech Biopharm Corporation
| Country | Taiwan |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Manish Chawla |
Contact Details
Address: No. 36, Ruiguang Road Taipei, 114 Taiwan | |
| Phone | 886 2 7721 8877 |
| Website | intechbiopharm.com |
Stock Details
| Ticker Symbol | 6461 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006461007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shuhui Chen | Chief Accountant and Chief Corporate Governance Officer |
| Wei Xiu Wu | General Manager |
| Qirui Li | Representative |
| Xianzhi Pi | Special Assistant to the Chairman and Strategic Development Coordinator |
| Dr. Manish Chawla | President and Chief Scientific Officer |
| Chien-Yiu Yang | Finance Division Head |